Physician profile
Jacob Jan Hendrik Bleesing
NPI 1841220167
$37,382.77
in general payments reported to CMS, 2019-2025
5 companies · $2,804 in 2025
The $2,804 reported for 2025 was more than what 99% of Clinical & Laboratory Immunology (Pediatrics) providers received nationally (typical 2025 total: $120).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $32K · 2023: $2,936 · 2025: $2,804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,636 · Food and Beverage: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,636.00 |
| Food and Beverage | $103.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $24,360.00 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $9,218.98 | 2022 | |
| Sarepta Therapeutics, INC. | $2,700.00 | 2025 | |
| Pharming Healthcare, INC. | $1,000.00 | 2022-2023 | Joenja |
| Sobi, INC | $103.79 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Bleesing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.